Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05616949 · ClinicalTrials.gov registry record · NA
Peer Recovery Support Services for Individuals in Recovery Residences on MOUD
A NA study of Opioid Use Disorder and Substance Use Disorder, sponsored by Potomac Health Foundations.
- Active
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT05616949: Active NA study of Opioid Use Disorder and Substance Use Disorder, sponsored by Potomac Health Foundations.
NCT05616949 is a NA study of Opioid Use Disorder and Substance Use Disorder that is active but no longer recruiting, run by Potomac Health Foundations. The registered enrollment target is 50 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05616949, a NA study of Opioid Use Disorder and Substance Use Disorder, is active but no longer recruiting, sponsored by Potomac Health Foundations.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The United States is experiencing an unprecedented opioid epidemic with a rapid increase in overdose deaths. Medications for opioid use disorder (MOUD) including methadone, buprenorphine, and extended-release naltrexone are efficacious and the recommended standard of care, yet barriers to sustained MOUD treatment reduce the overall efficacy of MOUD. Rates of MOUD retention are alarmingly low and MOUD dropout predicts opioid use/relapse, overdose, and death. While previous research has identified predictors of MOUD retention and adherence, there are no evidence-based interventions to improve MOUD retention. Recovery support services are a broad set of strategies to promote healthy outcomes among individuals with substance use disorder (SUD) that are typically separate from standard professional treatment. Among those strategies most utilized are peer recovery support services (PRSS) and recovery residences (RRs). PRSS include coaching, mentoring, education, and other supports delivered by individuals uniquely qualified by their lived experience with SUD. PRSS are increasingly utilized in a range of clinical settings, and advantages of PRSS include inherent shared understanding of addiction and a high degree of acceptance and understanding that is not found in most professional relationships. Existing research tentatively supports PRSS; however, the evidence to date is sparse and comes with significant methodological limitations and inconsistencies that make it difficult to conclude the efficacy of PRSS. No studies have examined the role of PRSS in promoting retention in MOUD. RRs provide a supportive living environment for persons in recovery from SUD and are widely utilized in the United States with an estimated 17,943 residences in 2020. Despite their proliferation, the evidence for RRs is only moderate and diminished by methodological weaknesses. Further, individuals on MOUD seeking housing through RRs often face increased MOUD-related stigma or may be disqualifi
Primary Outcome
Primary Outcome: Cumulative MOUD retention on all follow-up assessments for the following data sources: 1) Time Line Follow Back; 2) the Maryland PDMP; and 3) Patient Health Records.
Conditions Studied
Interventions
- BEHAVIORAL Treatment as Usual (TAU) (Arm 1)
- BEHAVIORAL Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2)
Study Locations (2)
Maryland
- Maryland Treatment Centers - Baltimore
- Maryland Treatment Centers/Avery Road Treatment Center - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-07-14 |
| Est. Completion | 2025-09-29 |
| Phase | NA |
What the registry record for NCT05616949 still lists
NCT05616949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Treatment as Usual (TAU) (Arm 1) is the first listed.
NCT05616949 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05616949 about?
NCT05616949 is a clinical study titled "Peer Recovery Support Services for Individuals in Recovery Residences on MOUD". The United States is experiencing an unprecedented opioid epidemic with a rapid increase in overdose deaths. Medications for opioid use disorder (MOUD) including methadone, buprenorphine, and extended-release naltrexone are efficacious and the recommended standard of care, yet barriers to sustained ...
What is the current status of trial NCT05616949?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2023-07-14. Estimated completion is 2025-09-29.
What conditions does trial NCT05616949 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Substance Use Disorder.
What interventions are being tested in trial NCT05616949?
The interventions under investigation include: Treatment as Usual (TAU) (Arm 1) (BEHAVIORAL), Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05616949?
This trial is sponsored by Potomac Health Foundations, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05616949 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05616949's enrollment target sits among peer trials
50 172nd of 257 higher than 80 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
Using Facebook to Support Opioid Recovery Among American Indian Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI